CytomX Therapeutics (CTMX) News Today → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free CTMX Stock Alerts $1.63 -0.05 (-2.98%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to "Hold"americanbankingnews.com - April 24 at 4:22 AMCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by StockNews.commarketbeat.com - April 23 at 11:12 PMJP Morgan Upgrades CytomX Therapeutics (CTMX)msn.com - April 23 at 4:53 AMCytomX Therapeutics (NASDAQ:CTMX) Upgraded to "Neutral" at JPMorgan Chase & Co.americanbankingnews.com - April 23 at 3:48 AMCytomX upgraded to Neutral at J.P Morganmsn.com - April 22 at 12:54 PMCytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Neutral at JPMorgan Chase & Co.marketbeat.com - April 22 at 8:35 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in Marchamericanbankingnews.com - April 18 at 5:54 AMCytomX Therapeutics, Inc. (CTMX)finance.yahoo.com - April 17 at 11:58 PMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Updatemarketbeat.com - April 16 at 4:34 PMCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumorsglobenewswire.com - April 8 at 8:00 AMCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellasglobenewswire.com - April 3 at 8:00 AMCytomX Therapeutics executive sells over $26k in company stockinvesting.com - March 23 at 9:57 AMCytomX Therapeutics executive sells shares worth over $6,000investing.com - March 23 at 9:57 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Lloyd A. Rowland Sells 5,268 Sharesinsidertrades.com - March 22 at 11:12 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Sells 5,268 Sharesmarketbeat.com - March 21 at 7:58 PMCytomX Therapeutics Appoints Dr. Zhen Su to Board of Directorsglobenewswire.com - March 21 at 8:00 AMCytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellasglobenewswire.com - March 18 at 8:00 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Significant Growth in Short Interestmarketbeat.com - March 15 at 11:58 PMResearch Analysts Issue Forecasts for CytomX Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CTMX)marketbeat.com - March 15 at 8:15 AMCytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - March 13 at 10:30 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN) and CytomX Therapeutics (CTMX)markets.businessinsider.com - March 12 at 1:32 PMJ.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)markets.businessinsider.com - March 12 at 1:32 PMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 12 at 1:32 PMWhy Is CytomX Therapeutics (CTMX) Stock Down 18% Today?investorplace.com - March 12 at 9:12 AMWhy Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarketbenzinga.com - March 12 at 8:31 AMStocks to Watch: Oracle, Mission Produce, CytomX Therapeuticsmarketwatch.com - March 11 at 8:47 PMCytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidatemarketwatch.com - March 11 at 8:47 PMRecap: CytomX Therapeutics Q4 Earningsbenzinga.com - March 11 at 8:47 PMCytomX Therapeutics Reports 2023 Financial Results and Provides Business Updateglobenewswire.com - March 11 at 4:10 PMCytomX Therapeutics's Earnings Outlookbenzinga.com - March 8 at 12:34 PMCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024globenewswire.com - March 4 at 8:00 AMBMY Oct 2024 45.000 putca.finance.yahoo.com - February 28 at 12:48 AMBMY Aug 2024 60.000 callca.finance.yahoo.com - February 27 at 7:48 PMBMY Apr 2024 52.000 putca.finance.yahoo.com - February 27 at 7:48 PMCytomX Therapeutics to Present at Upcoming March Investor Conferencesglobenewswire.com - February 27 at 8:00 AMShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Decreases By 5.3%marketbeat.com - February 16 at 6:57 PMCytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29%finance.yahoo.com - February 13 at 7:53 AMSangamo stock soars 37% on updates for Fabry disease therapymsn.com - February 12 at 4:51 PMCytomX Therapeutics Inc CTMXmorningstar.com - February 9 at 7:18 PMCytomX Therapeutics Inc (CTMX)investing.com - February 6 at 9:12 AMCytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Above 50-Day Moving Average of $1.52marketbeat.com - February 3 at 4:46 AMWill These 3 Pharma Stocks Leave Investors Triumphant in 2024?stocknews.com - February 2 at 5:32 PMCytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bfinance.yahoo.com - January 24 at 11:30 AMIonis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goalfinance.yahoo.com - January 23 at 6:11 PMAllakos (ALLK) Plummets 60% on Ending Development of Lead Drugfinance.yahoo.com - January 17 at 4:01 PMAdaptimmune (ADAP) Surges More Than 80% in a Month: Here's Whyfinance.yahoo.com - January 16 at 1:12 PMShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Rises By 35.5%marketbeat.com - January 15 at 8:57 PMAmicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Whyfinance.yahoo.com - January 12 at 1:51 PMCytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conferencefinance.yahoo.com - January 12 at 8:51 AMCautious Hold on CytomX Amid Awaiting Clinical Validation and Financial Outlookmarkets.businessinsider.com - January 10 at 12:38 PM Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now CTMX Media Mentions By Week CTMX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.500.43▲Average Medical News Sentiment CTMX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼102▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vistagen Therapeutics News Today Eliem Therapeutics News Today Karyopharm Therapeutics News Today Nuvectis Pharma News Today Repare Therapeutics News Today FibroGen News Today OptiNose News Today Citius Pharmaceuticals News Today Coya Therapeutics News Today Sagimet Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
